758 related articles for article (PubMed ID: 1666101)
1. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
2. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
[TBL] [Abstract][Full Text] [Related]
3. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection.
Hines DL; Cutting JA; Dietrich DL; Walsh JA
J Am Vet Med Assoc; 1991 Nov; 199(10):1428-30. PubMed ID: 1666097
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure.
Legendre AM; Hawks DM; Sebring R; Rohrbach B; Chavez L; Chu HJ; Acree WM
J Am Vet Med Assoc; 1991 Nov; 199(10):1456-62. PubMed ID: 1666103
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection.
Clark N; Kushner NN; Barrett CB; Kensil CR; Salsbury D; Cotter S
J Am Vet Med Assoc; 1991 Nov; 199(10):1433-43. PubMed ID: 1666099
[TBL] [Abstract][Full Text] [Related]
7. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of three commercial feline leukemia virus vaccines against methylprednisolone acetate-augmented oronasal challenge exposure with virulent virus.
Pedersen NC; Johnson L
J Am Vet Med Assoc; 1991 Nov; 199(10):1453-5. PubMed ID: 1666102
[TBL] [Abstract][Full Text] [Related]
9. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
Grosenbaugh DA; Leard T; Pardo MC
J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
[TBL] [Abstract][Full Text] [Related]
10. Year two of follow-up evaluation of a randomized, blind field trial of a commercial feline leukemia virus vaccine.
Scarlett JM; Pollock RV
J Am Vet Med Assoc; 1991 Nov; 199(10):1431-2. PubMed ID: 1666098
[TBL] [Abstract][Full Text] [Related]
11. Antibody response of kittens after vaccination followed by exposure to feline leukemia virus-infected cats.
Hawks DM; Legendre AM; Rohrbach BW; Sebring R; Chavez L; Chu HJ; Acree WM
J Am Vet Med Assoc; 1991 Nov; 199(10):1463-9. PubMed ID: 1666104
[TBL] [Abstract][Full Text] [Related]
12. Development of a genetically engineered vaccine against feline leukemia virus infection.
Kensil CR; Barrett C; Kushner N; Beltz G; Storey J; Patel U; Recchia J; Aubert A; Marciani D
J Am Vet Med Assoc; 1991 Nov; 199(10):1423-7. PubMed ID: 1666096
[TBL] [Abstract][Full Text] [Related]
13. Development of a whole killed feline leukemia virus vaccine.
York SM; York CJ
J Am Vet Med Assoc; 1991 Nov; 199(10):1419-22. PubMed ID: 1666095
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection.
Lehmann R; Joller H; Haagmans BL; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):61-9. PubMed ID: 1337403
[TBL] [Abstract][Full Text] [Related]
15. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
16. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
Lafrado LJ
J Am Vet Med Assoc; 1994 Mar; 204(6):914-7. PubMed ID: 8188511
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
[TBL] [Abstract][Full Text] [Related]
19. Toward vaccination against feline leukemia virus and feline immunodeficiency virus infections.
Osterhaus AD; Weijer K; Siebelink KH; Rimmelzwaan GF; Bosch ML
J Am Vet Med Assoc; 1991 Nov; 199(10):1443-6. PubMed ID: 1666100
[No Abstract] [Full Text] [Related]
20. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
Grosenbaugh DA; Leard T; Pardo MC; Motes-Kreimeyer L; Royston M
Vet Ther; 2004; 5(4):258-62. PubMed ID: 15719325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
